D
Teva Pharmaceutical Industries Limited
TEVA
$16.71
$0.382.33%
D
Sell
9/20/2024Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 9/20/2024 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 183.06% from -$124M to $103M, EBIT increased 23.79% from $660M to $817M, and total revenue increased 9.03% from $3.82B to $4.16B.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 9/20/2024 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 183.06% from -$124M to $103M, EBIT increased 23.79% from $660M to $817M, and total revenue increased 9.03% from $3.82B to $4.16B.
D
Sell
5/22/2023Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 5/22/2023 due to a major decline in the efficiency index, growth index and volatility index. Operating cash flow declined 114.9% from $973M to -$145M, EBIT declined 22.07% from $639M to $498M, and total revenue declined 5.74% from $3.88B to $3.66B.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 5/22/2023 due to a major decline in the efficiency index, growth index and volatility index. Operating cash flow declined 114.9% from $973M to -$145M, EBIT declined 22.07% from $639M to $498M, and total revenue declined 5.74% from $3.88B to $3.66B.
D
Sell
2/13/2023Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 2/13/2023 due to a decline in the total return index, efficiency index and solvency index. Net income declined 2,280.36% from $56M to -$1.22B, debt to equity increased from 2.43 to 2.7, and total capital declined 2.55% from $31.14B to $30.35B.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 2/13/2023 due to a decline in the total return index, efficiency index and solvency index. Net income declined 2,280.36% from $56M to -$1.22B, debt to equity increased from 2.43 to 2.7, and total capital declined 2.55% from $31.14B to $30.35B.
D
Sell
1/30/2023Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 1/30/2023 due to a noticeable increase in the total return index and volatility index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 1/30/2023 due to a noticeable increase in the total return index and volatility index.
D
Sell
11/7/2022Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 11/7/2022 due to a significant decline in the growth index and solvency index. The quick ratio declined from 0.59 to 0.52, and total revenue declined 5.04% from $3.79B to $3.6B.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 11/7/2022 due to a significant decline in the growth index and solvency index. The quick ratio declined from 0.59 to 0.52, and total revenue declined 5.04% from $3.79B to $3.6B.
D
Sell
7/28/2022Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 7/28/2022 due to a significant increase in the growth index, volatility index and valuation index. Operating cash flow increased 351.02% from -$49M to $123M, earnings per share increased from -$0.8627 to -$0.21, and total revenue increased 3.41% from $3.66B to $3.79B.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 7/28/2022 due to a significant increase in the growth index, volatility index and valuation index. Operating cash flow increased 351.02% from -$49M to $123M, earnings per share increased from -$0.8627 to -$0.21, and total revenue increased 3.41% from $3.66B to $3.79B.
D
Sell
5/31/2022Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index and total return index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index and total return index.
D
Sell
5/13/2022Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/6/2022Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 5/6/2022 due to a significant decline in the valuation index, efficiency index and volatility index. Net income declined 500.63% from -$159M to -$955M, and total capital declined 3.64% from $34.84B to $33.57B.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 5/6/2022 due to a significant decline in the valuation index, efficiency index and volatility index. Net income declined 500.63% from -$159M to -$955M, and total capital declined 3.64% from $34.84B to $33.57B.
D
Sell
4/18/2022Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 4/18/2022 due to an increase in the volatility index and total return index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 4/18/2022 due to an increase in the volatility index and total return index.
D
Sell
2/11/2022Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 2/11/2022 due to a large decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.26 to -$0.1442, net income declined 154.45% from $292M to -$159M, and operating cash flow declined 13.8% from $529M to $456M.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 2/11/2022 due to a large decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.26 to -$0.1442, net income declined 154.45% from $292M to -$159M, and operating cash flow declined 13.8% from $529M to $456M.
D
Sell
2/9/2022Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 2/9/2022 due to an increase in the volatility index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 2/9/2022 due to an increase in the volatility index.
D
Sell
1/10/2022Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 1/10/2022 due to a decline in the total return index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from D+ on 1/10/2022 due to a decline in the total return index.
D
Sell
11/3/2021Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 11/3/2021 due to a significant increase in the valuation index, total return index and growth index. Operating cash flow increased 142.66% from $218M to $529M, and earnings per share increased from $0.1877 to $0.26.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D+ from D on 11/3/2021 due to a significant increase in the valuation index, total return index and growth index. Operating cash flow increased 142.66% from $218M to $529M, and earnings per share increased from $0.1877 to $0.26.
D
Sell
11/12/2019Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 11/12/2019 due to a noticeable increase in the growth index, solvency index and volatility index. Operating cash flow increased 243.17% from -$227M to $325M, earnings per share increased from -$0.631 to -$0.29, and debt to equity declined from 2.04 to 1.96.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 11/12/2019 due to a noticeable increase in the growth index, solvency index and volatility index. Operating cash flow increased 243.17% from -$227M to $325M, earnings per share increased from -$0.631 to -$0.29, and debt to equity declined from 2.04 to 1.96.
D
Sell
8/13/2019Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 8/13/2019 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.1 to -$0.631, operating cash flow declined 302.68% from $112M to -$227M, and debt to equity increased from 1.95 to 2.04.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 8/13/2019 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.1 to -$0.631, operating cash flow declined 302.68% from $112M to -$227M, and debt to equity increased from 1.95 to 2.04.
D
Sell
8/5/2019Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 8/5/2019 due to an increase in the volatility index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to D from D- on 8/5/2019 due to an increase in the volatility index.
D
Sell
6/27/2019Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 6/27/2019 due to a large decline in the efficiency index, total return index and volatility index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D- from D on 6/27/2019 due to a large decline in the efficiency index, total return index and volatility index.
D
Sell
8/4/2017Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from C- on 8/4/2017 due to a major decline in the efficiency index, growth index and solvency index. Earnings per share declined from $0.57 to -$5.94, net income declined 1,025.58% from $645M to -$5.97B, and debt to equity increased from 1.14 to 1.44.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D from C- on 8/4/2017 due to a major decline in the efficiency index, growth index and solvency index. Earnings per share declined from $0.57 to -$5.94, net income declined 1,025.58% from $645M to -$5.97B, and debt to equity increased from 1.14 to 1.44.
C
Hold
7/31/2017Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to C- from D+ on 7/31/2017 due to a noticeable increase in the growth index, solvency index and efficiency index. Net income increased 166.29% from -$973M to $645M, earnings per share increased from -$1.0227 to $0.57, and debt to equity declined from 1.2 to 1.14.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to C- from D+ on 7/31/2017 due to a noticeable increase in the growth index, solvency index and efficiency index. Net income increased 166.29% from -$973M to $645M, earnings per share increased from -$1.0227 to $0.57, and debt to equity declined from 1.2 to 1.14.
D
Sell
2/17/2017Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D+ from C- on 2/17/2017 due to a significant decline in the valuation index, growth index and total return index. Earnings per share declined from $0.35 to -$1.0227, and operating cash flow declined 2.46% from $1.46B to $1.43B.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to D+ from C- on 2/17/2017 due to a significant decline in the valuation index, growth index and total return index. Earnings per share declined from $0.35 to -$1.0227, and operating cash flow declined 2.46% from $1.46B to $1.43B.
C
Hold
1/4/2017Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C- from C on 1/4/2017 due to a large decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.42 to 1.17, and the quick ratio declined from 0.86 to 0.5.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C- from C on 1/4/2017 due to a large decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.42 to 1.17, and the quick ratio declined from 0.86 to 0.5.
C
Hold
8/5/2016Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C from C+ on 8/5/2016 due to a noticeable decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.62 to $0.2, operating cash flow declined 30.01% from $1.38B to $963M, and debt to equity increased from 0.38 to 0.42.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C from C+ on 8/5/2016 due to a noticeable decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.62 to $0.2, operating cash flow declined 30.01% from $1.38B to $963M, and debt to equity increased from 0.38 to 0.42.
C
Hold
7/12/2016Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to C+ from C on 7/12/2016 due to an increase in the volatility index, valuation index and dividend index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to C+ from C on 7/12/2016 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
6/24/2016Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C from C+ on 6/24/2016 due to a noticeable decline in the volatility index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C from C+ on 6/24/2016 due to a noticeable decline in the volatility index.
C
Hold
4/25/2016Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C+ from B- on 4/25/2016 due to a large decline in the volatility index and total return index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to C+ from B- on 4/25/2016 due to a large decline in the volatility index and total return index.
B
Buy
3/14/2016Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B- from B on 3/14/2016 due to a decline in the total return index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B- from B on 3/14/2016 due to a decline in the total return index.
B
Buy
2/16/2016Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B from B- on 2/16/2016 due to a major increase in the growth index, solvency index and dividend index. Earnings per share increased from $0.12 to $0.5587, the quick ratio increased from 0.48 to 0.95, and operating cash flow increased 47.76% from $1.09B to $1.62B.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B from B- on 2/16/2016 due to a major increase in the growth index, solvency index and dividend index. Earnings per share increased from $0.12 to $0.5587, the quick ratio increased from 0.48 to 0.95, and operating cash flow increased 47.76% from $1.09B to $1.62B.
B
Buy
11/9/2015Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B- from B on 11/9/2015 due to a decline in the total return index, volatility index and valuation index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B- from B on 11/9/2015 due to a decline in the total return index, volatility index and valuation index.
B
Buy
10/30/2015Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B from B+ on 10/30/2015 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $0.63 to $0.12, operating cash flow declined 26.15% from $1.48B to $1.09B, and total revenue declined 2.88% from $4.97B to $4.82B.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B from B+ on 10/30/2015 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $0.63 to $0.12, operating cash flow declined 26.15% from $1.48B to $1.09B, and total revenue declined 2.88% from $4.97B to $4.82B.
B
Buy
9/10/2015Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B+ from A- on 9/10/2015 due to a decline in the total return index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B+ from A- on 9/10/2015 due to a decline in the total return index.
A
Buy
8/26/2015Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to A- from B+ on 8/26/2015 due to a major increase in the total return index and volatility index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to A- from B+ on 8/26/2015 due to a major increase in the total return index and volatility index.
B
Buy
3/24/2015Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B+ from A- on 3/24/2015 due to a decline in the valuation index and dividend index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B+ from A- on 3/24/2015 due to a decline in the valuation index and dividend index.
A
Buy
3/9/2015Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to A- from B+ on 3/9/2015 due to an increase in the volatility index, valuation index and efficiency index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to A- from B+ on 3/9/2015 due to an increase in the volatility index, valuation index and efficiency index.
B
Buy
11/28/2014Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B+ from B on 11/28/2014 due to an increase in the total return index, volatility index and solvency index.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B+ from B on 11/28/2014 due to an increase in the total return index, volatility index and solvency index.
B
Buy
11/13/2014Downgrade
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B from B+ on 11/13/2014 due to a noticeable decline in the volatility index, total return index and dividend index.
Teva Pharmaceutical Industries Limited (TEVA) was downgraded to B from B+ on 11/13/2014 due to a noticeable decline in the volatility index, total return index and dividend index.
B
Buy
8/4/2014Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B+ from B on 8/4/2014 due to a major increase in the valuation index, growth index and total return index. Operating cash flow increased 17.26% from $898M to $1.05B, EBIT increased 2.26% from $1.06B to $1.09B, and total revenue increased 0.88% from $5B to $5.05B.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B+ from B on 8/4/2014 due to a major increase in the valuation index, growth index and total return index. Operating cash flow increased 17.26% from $898M to $1.05B, EBIT increased 2.26% from $1.06B to $1.09B, and total revenue increased 0.88% from $5B to $5.05B.
B
Buy
5/5/2014Upgraded
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B from B- on 5/5/2014 due to a major increase in the volatility index, growth index and total return index. Earnings per share increased from $0.4486 to $0.87, and operating cash flow increased 10.05% from $816M to $898M.
Teva Pharmaceutical Industries Limited (TEVA) was upgraded to B from B- on 5/5/2014 due to a major increase in the volatility index, growth index and total return index. Earnings per share increased from $0.4486 to $0.87, and operating cash flow increased 10.05% from $816M to $898M.
NYSE
03/17/2025 4:00PM Eastern
Quotes delayed
